High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care?

Biologic therapies targeting the interleukin (IL)-23 and IL-17 pathways represent the current standard of care for moderate-to-severe psoriasis, with demonstrated high efficacy and favorable safety profiles. However, many patients still experience residual disease, treatment fatigue related to lifelong injectable therapy, or rapid relapse following treatment withdrawal. Emerging evidence suggests that the next frontier in psoriasis management lies not in further incremental efficacy gains but in optimizing dosing strategies to reduce treatment burden and extend drug-free remission. Early intervention, dose spacing, and higher-dose IL-23 inhibitors have been associated with deeper and more sustained disease control, potentially mediated by the durable suppression of pathogenic tissue-resident memory T cells. ORKA-001 is a next-generation, extended half-life IL-23p19 monoclonal antibody engineered with Fc modifications to markedly prolong systemic exposure. Phase 1 data demonstrate a terminal half-life of approximately 100 days, sustained pharmacodynamic suppression of IL-23 signaling, and a favorable safety profile. Ongoing clinical development aims to determine whether high-dose, long-acting IL-23 inhibition can enable prolonged remission with infrequent or no maintenance dosing, challenging current paradigms of lifelong continuous therapy in psoriasis.